公开(公告)号：US06660486B2

公开(公告)日：2003-12-09

申请号：US09872639

申请日：2001-05-31

Applicant: Steven R. Binder ,  Jodi L. Goodrich ,  Zara Safarian

Inventor： Steven R. Binder ,  Jodi L. Goodrich ,  Zara Safarian

IPC: G01N3353

CPC classification number: G01N33/96 ,  G01N2333/9108 ,  Y10S435/973

Abstract: Analyses of serum samples for the presence and amount of either of the two subunits of human Factor XIII protein are used as a means of eliminating a significant source of error that arises in the testing of serum and plasma. For serum samples, a negative result of an analysis for the presence of subunit a is a means of verifying that a sample is indeed serum, while a negative or positive result for subunit a serves to distinguish serum (negative) from plasma (positive). A positive result for the presence of subunit b is a means of verifying that the sample is either serum or plasma and not any other biological fluid. A quantitative analysis of subunit b is a means of verifying that the sample is of the intended volume rather than having been reduced in volume due to improper sampling. A quantitative analysis of subunit b is also a means of verifying the dilution of a sample of either serum or plasma.

Abstract translation: 使用血清样品对人因子XIII蛋白的两个亚基中任一个的存在和量的分析作为消除在血清和血浆测试中出现的重大误差源的手段。 对于血清样品，分析亚单位a的存在的阴性结果是验证样品确实为血清的方法，而亚单位a的阴性或阳性结果用于区分血清（阴性）和血浆（阳性）。 亚单位b的存在的阳性结果是验证样品是血清或血浆而不是任何其他生物流体的手段。 亚基b的定量分析是验证样品是否具有预期体积的手段，而不是由于不正确的取样而体积减小。 亚基b的定量分析也是验证血清或血浆样品稀释度的一种手段。

公开(公告)号：US5104622A

公开(公告)日：1992-04-14

申请号：US676658

申请日：1991-03-28

Applicant: Steven R. Binder

Inventor： Steven R. Binder

IPC: G01N30/88 ,  G01N33/94

CPC classification number: G01N33/94 ,  G01N30/88

Abstract: Biological fluid test samples are analyzed for a broad spectrum of drugs, including benzodiazepines, amphetamines, tricyclic antidepressants and opiates, in a single isocratic analysis using a chromatographic column system containing three analytical columns--an anion exchange column, a reversed phase column and a cation exchange column. A pre-column is also included to purge the sample of salts, proteins, peptides and hydrophilic anions. Carrier liquids containing acetonitrile at various strengths are used for distribution of the various drugs among the columns, elution of the drugs from the columns, and column purging and conditioning. The system readily lends itself to automation, automatic periodic sampling, and component identification and quantification.

Abstract translation: 在使用含有三个分析柱的色谱柱系统（阴离子交换柱，反相柱和阳离子）的单一等度分析中，分析生物流体测试样品中的广谱药物，包括苯并二氮杂，安非他命，三环抗抑郁药和阿片剂 交换列。 还包括预柱以清除盐，蛋白质，肽和亲水性阴离子的样品。 使用各种强度的含有乙腈的载体液体在柱中分配各种药物，药物从柱中洗脱，以及柱清洗和调理。 该系统易于自动化，自动定期采样，组件识别和量化。

公开(公告)号：US06984497B2

公开(公告)日：2006-01-10

申请号：US10118413

申请日：2002-04-05

Applicant: Michael I. Watkins ,  Steven R. Binder ,  Aleksander Raskin

Inventor： Michael I. Watkins ,  Steven R. Binder ,  Aleksander Raskin

IPC: G01N33/53

CPC classification number: G01N33/54393 ,  Y10S435/962

Abstract: Water-soluble polymer is added to the liquid phase in a heterogeneous a immunoassay of serum, the polymer having monomers in common with monomers of the solid phase surface. This reduces non-specific binding of IgG's from the serum to the solid phase surface and thereby reduces the occurrence of false positive readings in the immunoassay.

公开(公告)号：US6156179A

公开(公告)日：2000-12-05

申请号：US112725

申请日：1998-07-09

Applicant: Steven R. Binder ,  Bryan H. Ikeda ,  Caroline Scolari

Inventor： Steven R. Binder ,  Bryan H. Ikeda ,  Caroline Scolari

IPC: G01N33/53 ,  G01N33/68 ,  G01N27/26

CPC classification number: G01N33/53 ,  G01N33/6854

Abstract: The present invention is generally directed to the analysis of biological samples. More particularly, the present invention is directed to automated sample analysis for paraproteins using immunosubtraction, capillary electrophoresis and Fourier transformation analysis.

Abstract translation: 本发明一般涉及生物样品的分析。 更具体地，本发明涉及使用免疫沉降，毛细管电泳和傅里叶变换分析的蛋白质的自动化样品分析。

公开(公告)号：US5922184A

公开(公告)日：1999-07-13

申请号：US895247

申请日：1997-07-21

Applicant: Steven R. Binder ,  Caroline Scolari ,  Robert K. Likuski

Inventor： Steven R. Binder ,  Caroline Scolari ,  Robert K. Likuski

IPC: G01N27/447 ,  G01N27/26

CPC classification number: G01N27/44721 ,  G01N27/44717

Abstract: Identification and quantification of paraproteins in a sample is achieved by Fourier analysis of mobility-based electropherograms obtained from capillary electrophoresis. The use of a computer algorithm to analyze capillary electrophoresis data, provides the clinician with methods of detecting levels of paraproteins in serum as low as 0.05 g/dL. Additionally, an individual paraprotein can be located on an electropherogram and used to monitor its increased or decreased production in an individual.

Abstract translation: 通过对从毛细管电泳获得的基于迁移率的电泳图进行傅立叶分析来实现样品中蛋白质的鉴定和定量。 使用计算机算法分析毛细管电泳数据，为临床医生提供了检测血清中蛋白质水平低至0.05 g / dL的方法。 另外，个体副蛋白可以位于电泳图上，并用于监测个体中增加或减少的生产。

公开(公告)号：US5416023A

公开(公告)日：1995-05-16

申请号：US271390

申请日：1994-07-06

Applicant: Steven R. Binder ,  David L. King

Inventor： Steven R. Binder ,  David L. King

IPC: G01N30/02 ,  G01N30/06 ,  G01N30/08 ,  G01N30/14 ,  G01N30/34 ,  G01N30/46 ,  G01N30/74 ,  G01N30/86 ,  G01N30/88

CPC classification number: G01N30/461 ,  G01N30/88 ,  G01N2030/027 ,  G01N2030/085 ,  G01N2030/8804 ,  G01N2030/8813 ,  G01N2030/8831 ,  G01N30/02 ,  G01N30/06 ,  G01N30/14 ,  G01N30/34 ,  G01N30/468 ,  G01N30/74 ,  G01N30/8606 ,  G01N30/8679 ,  Y10S436/901 ,  Y10T436/14 ,  Y10T436/145555 ,  Y10T436/17 ,  Y10T436/25 ,  Y10T436/25125 ,  Y10T436/255

Abstract: Biological samples are analyzed for benzodiazepines in a single isocratic analysis using a chromatographic column system containing an immobilized enzyme reactor which cleaves glucuronic acid-conjugated benzodiazepines, an anion exchange column, a hydrophobic cation exchange column and a reverse-phase analytical column. Preferred methods of performing the analysis further involve the use of a hydrophobic cation exchange precolumn prior to the anion exchange column. The system readily lends itself to automation, automatic periodic sampling and benzodiazepine identification and quantification. The system is particularly well adapted to the determination and identification of benzodiazepines in urine samples.

Abstract translation: 在使用含有固定化酶反应器的色谱柱系统的单一等度分析中分析生物样品中的苯并二氮杂，所述固定化酶反应器切割葡糖醛酸 - 共轭苯并二氮杂，阴离子交换柱，疏水性阳离子交换柱和反相分析柱。 执行分析的优选方法还涉及在阴离子交换柱之前使用疏水性阳离子交换预柱。 该系统易于自动化，自动定期取样和苯二氮卓鉴定和定量。 该系统特别适用于尿液样品中苯二氮卓类的测定和鉴定。

公开(公告)号：US5057437A

公开(公告)日：1991-10-15

申请号：US225108

申请日：1988-07-27

Applicant: Steven R. Binder

Inventor： Steven R. Binder

IPC: G01N30/14 ,  G01N30/46 ,  G01N30/88 ,  G01N33/94

CPC classification number: G01N33/94 ,  G01N30/88 ,  G01N2030/8804 ,  G01N2030/8813 ,  G01N2030/8831 ,  Y10S436/815 ,  Y10S436/901 ,  Y10T436/255

Abstract: Biological fluid test samples are analyzed for a broad spectrum of drugs, including benzodiazepines, amphetamines, tricyclic antidepressants and opiates, in a single isocratic analysis using a chromatographic column system containing three analytical columns--an anion exchange column, a reversed phase column and a cation exchange column. A pre-column is also included to purge the sample of salts, proteins, peptides and hydrophilic anions. Carrier liquids containing acetonitrile at various strengths are used for distribution of the various drugs among the columns, elution of the drugs from the columns, and column purging and conditioning. The system readily lends itself to automation, automatic periodic sampling, and component identification and quantification.

公开(公告)号：US07138245B2

公开(公告)日：2006-11-21

申请号：US10965608

申请日：2004-10-13

Applicant: Steven R. Binder ,  Jodi L. Goodrich ,  Zara Safarian

Inventor： Steven R. Binder ,  Jodi L. Goodrich ,  Zara Safarian

IPC: G01N33/53

CPC classification number: G01N33/96 ,  G01N2333/9108 ,  Y10S435/973

Abstract: Analyses of serum samples for the presence and amount of either of the two subunits of human Factor XIII protein are used as a means of eliminating a significant source of error that arises in the testing of serum and plasma. For serum samples, a negative result of an analysis for the presence of subunit a is a means of verifying that a sample is indeed serum, while a negative or positive result for subunit a serves to distinguish serum (negative) from plasma (positive). A positive result for the presence of subunit b is a means of verifying that the sample is either serum or plasma and not any other biological fluid. A quantitative analysis of subunit b is a means of verifying that the sample is of the intended volume rather than having been reduced in volume due to improper sampling. A quantitative analysis of subunit b is also a means of verifying the dilution of a sample of either serum or plasma.

公开(公告)号：US07141362B2

公开(公告)日：2006-11-28

申请号：US10966650

申请日：2004-10-14

Applicant: Steven R. Binder ,  Jodi L. Goodrich ,  Zara Safarian

Inventor： Steven R. Binder ,  Jodi L. Goodrich ,  Zara Safarian

IPC: G01N33/53

CPC classification number: G01N33/96 ,  G01N2333/9108 ,  Y10S435/973

Abstract: Analyses of serum samples for the presence and amount of either of the two subunits of human Factor XIII protein are used as a means of eliminating a significant source of error that arises in the testing of serum and plasma. For serum samples, a negative result of an analysis for the presence of subunit a is a means of verifying that a sample is indeed serum, while a negative or positive result for subunit a serves to distinguish serum (negative) from plasma (positive). A positive result for the presence of subunit b is a means of verifying that the sample is either serum or plasma and not any other biological fluid. A quantitative analysis of subunit b is a means of verifying that the sample is of the intended volume rather than having been reduced in volume due to improper sampling. A quantitative analysis of subunit b is also a means of verifying the dilution of a sample of either serum or plasma.

公开(公告)号：US5352585A

公开(公告)日：1994-10-04

申请号：US084845

申请日：1993-06-29

Applicant: Steven R. Binder ,  David L. King

Inventor： Steven R. Binder ,  David L. King

IPC: G01N30/02 ,  G01N30/06 ,  G01N30/08 ,  G01N30/14 ,  G01N30/34 ,  G01N30/46 ,  G01N30/74 ,  G01N30/86 ,  G01N30/88

CPC classification number: G01N30/461 ,  G01N30/88 ,  G01N2030/027 ,  G01N2030/085 ,  G01N2030/8804 ,  G01N2030/8813 ,  G01N2030/8831 ,  G01N30/02 ,  G01N30/06 ,  G01N30/14 ,  G01N30/34 ,  G01N30/468 ,  G01N30/74 ,  G01N30/8606 ,  G01N30/8679 ,  Y10S436/901 ,  Y10T436/14 ,  Y10T436/145555 ,  Y10T436/17 ,  Y10T436/25 ,  Y10T436/25125 ,  Y10T436/255

Abstract: Biological samples are analyzed for benzodiazepines in a single isocratic analysis using a chromatographic column system containing an immobilized enzyme reactor which cleaves glucuronic acid-conjugated benzodiazepines, an anion exchange column, a hydrophobic cation exchange column and a reverse-phase analytical column. Preferred methods of performing the analysis further involve the use of a hydrophobic cation exchange precolumn prior to the anion exchange column. The system readily lends itself to automation, automatic periodic sampling and benzodiazepine identification and quantification. The system is particularly well adapted to the determination and identification of benzodiazepines in urine samples.

Abstract translation: 在使用含有固定化酶反应器的色谱柱系统的单一等度分析中分析生物样品中的苯并二氮杂，所述固定化酶反应器切割葡糖醛酸 - 共轭苯并二氮杂，阴离子交换柱，疏水性阳离子交换柱和反相分析柱。 执行分析的优选方法还涉及在阴离子交换柱之前使用疏水性阳离子交换预柱。 该系统易于自动化，自动定期取样和苯二氮卓鉴定和定量。 该系统特别适用于尿液样品中苯二氮卓类的测定和鉴定。